| Literature DB >> 34568262 |
Karolina Kalanj1, Ric Marshall2, Karl Karol3, Mirjana Kujundžić Tiljak4, Stjepan Orešković4.
Abstract
Background: The COVID-19 pandemic disrupted hospital care, as hospitals had to deal with a highly infectious virus, while at the same time continuing to fulfill the ongoing health service needs of their communities. This study examines the direct effects of COVID-19 on the delivery of inpatient care in Croatia. Materials andEntities:
Keywords: AR-DRG; COVID-19; data transparency; health system response; hospital admissions; pandemic
Mesh:
Year: 2021 PMID: 34568262 PMCID: PMC8459902 DOI: 10.3389/fpubh.2021.720948
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Figure 1Comparison of Total Monthly Admissions, COVID-19 Related and non-COVID-19 Admissions. Source: Monthly admission data from CHIF—January, February, March data is an average for the first quarter of 2020; Covid-19 admission data from PHI (PHI begun recording Covid-19 data on 14th April, 2020).
Comparison of DRG case activity before, and during Covid 19 in 2020.
|
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| ||
| PRE - MDC | 3,388 | 1,544 | 4,932 | 3,636 | 1,609 | 5,245 | 7% | 4% | 6% | 0.0003 |
| 01-Nervous system | 23,241 | 17,383 | 40,624 | 18,056 | 13,722 | 31,778 | −22% | −21% | −22% | <0.0001 |
| 02-Eye | 13,223 | 6,245 | 19,468 | 7,329 | 3,096 | 10,425 | −45% | −50% | −46% | <0.0001 |
| 03-Ear, nose, mouth and throat | 13,204 | 7,646 | 20,850 | 8,286 | 4,495 | 12,781 | −37% | −41% | −39% | <0.0001 |
| 04-Respiratory system | 19,350 | 19,343 | 38,693 | 18,662 | 19,392 | 38,054 | −4% | 0% | −2% | 00.4321 |
| 05-Circulatory system | 38,036 | 24,537 | 62,573 | 30,132 | 18,885 | 49,017 | −21% | −23% | −22% | <0.0001 |
| 06-Digestive system | 28,526 | 22,420 | 50,946 | 23,422 | 16,900 | 40,322 | −18% | −25% | −21% | <0.0001 |
| 07-Hepatobiliary system and pancreas | 15,687 | 10,465 | 26,152 | 11,324 | 8,719 | 20,043 | −28% | −17% | −23% | <0.0001 |
| 08-Musculoskeletal system and connective tissue | 35,314 | 21,352 | 56,666 | 27,404 | 16,876 | 44,280 | −22% | −21% | −22% | <0.0001 |
| 09-Skin, subcutaneous tissue and breast | 12,542 | 7,298 | 19,840 | 8,338 | 5,090 | 13,428 | −34% | −30% | −32% | <0.0001 |
| 10-Endocrine, nutritional and metabolic diseases | 11,651 | 4,533 | 16,185 | 7,352 | 2,831 | 10,183 | −37% | −38% | −37% | <0.0001 |
| 11-Kidney and urinary tract | 14,933 | 11,697 | 26,630 | 11,852 | 9,183 | 21,035 | −21% | −21% | −21% | <0.0001 |
| 12- Male reproductive system | 5,093 | 3,010 | 8,103 | 3,719 | 1,931 | 5,650 | −27% | −36% | −30% | <0.0001 |
| 13- Female reproductive system | 12,590 | 7,758 | 20,348 | 9,062 | 5,920 | 14,982 | −28% | −24% | −26% | <0.0001 |
| 14-Pregnancy, childbirth and puerperium | 28,236 | 22,864 | 51,100 | 25,588 | 21,132 | 46,720 | −9% | −8% | −9% | <0.0001 |
| 15-Newborns and other neonates | 5,234 | 3,854 | 9,088 | 4,509 | 3,672 | 8,181 | −14% | −5% | −10% | <0.0001 |
| 16- Blood, blood forming organs, immunological | 3,268 | 2,323 | 5,591 | 2,428 | 1,910 | 4,338 | −26% | −18% | −22% | <0.0001 |
| 17- Hematological and solid neoplasms | 11,312 | 3,246 | 14,558 | 9,734 | 3,387 | 13,121 | −14% | 4% | −10% | <0.0001 |
| 18-Infectious and parasitic diseases | 5,726 | 5,915 | 11,641 | 4,745 | 5,371 | 10,116 | −17% | −9% | −13% | <0.0001 |
| 19-Mental diseases and disorders | 5,966 | 6,365 | 12,331 | 4,331 | 4,691 | 9,022 | −27% | −26% | −27% | <0.0001 |
| 20-Alcohol/drug use and induced disorders | 1,413 | 1,852 | 3,265 | 988 | 1,237 | 2,225 | −30% | −33% | −32% | <0.0001 |
| 21-Injuries, poisonings and toxic effects of drugs | 2,398 | 1,945 | 4,342 | 1,712 | 1,444 | 3,156 | −29% | −26% | −27% | <0.0001 |
| 22-Burns | 324 | 174 | 498 | 219 | 125 | 344 | −32% | −28% | −31% | <0.0001 |
| 23-Factors influencing health status | 5,629 | 1,181 | 6,811 | 4,384 | 1,022 | 5,406 | −22% | −13% | −21% | <0.0001 |
| ERROR DRG | 991 | 636 | 1,627 | 548 | 490 | 1,038 | −45% | −23% | −36% | <0.0001 |
|
|
|
|
|
|
|
| – | – | – |
|
Source: CHIF and authors calculation.
Figure 2Incidence Rate Ratio per MDC during 2020 as compared to period 2017–2019.
Difference in activity in Covid 19 related DRG classes before, and during Covid 19 in 2020.
|
|
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |||
| A06Z | Tracheostomy or ventilation > 95 | 1,951 | 1,231 | 3,181 | 2,424 | 1,492 | 3,916 | 24% | 21% | 23% | <0.0001 |
| E40Z | Resp sys dx + ventilator suppt | 139 | 155 | 295 | 271 | 212 | 483 | 94% | 36% | 64% | <0.0001 |
| E41Z | Resp sys dx + non-invas ventiln | 573 | 122 | 695 | 454 | 259 | 713 | −21% | 112% | 3% | 0.4925 |
| E62A | Respiratory infectn/inflamm + ccc | 765 | 1,148 | 1,914 | 971 | 1,284 | 2,255 | 27% | 12% | 18% | <0.0001 |
| E62B | Respiratory infectn/inflam + smcc | 3,146 | 4,169 | 7,315 | 5,230 | 5,762 | 10,992 | 66% | 38% | 50% | <0.0001 |
| E62C | Respiratory infectn/inflamm-cc | 1,571 | 2,904 | 4,475 | 2,484 | 3,690 | 6,174 | 58% | 27% | 38% | <0.0001 |
|
|
|
|
|
|
|
|
|
|
|
| |
Source: CHIF and authors calculation.
Figure 3Incidence Rate Ratio for COVID-19 related DRGs during 2020 as compared to period 2017–2019.
Difference in case activity in cancer and neoplasm related DRG classes before, and during Covid 19 in 2020.
|
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| ||
| B66A, B66B - nervous system neoplasms | 1,113 | 822 | 1,936 | 913 | 679 | 1,592 | −18% | −17% | −18% | <0.0001 |
| D60A, D60B - ear nose mouth and throat malignancy | 907 | 237 | 1,144 | 907 | 207 | 1,114 | 0% | −13% | −3% | 0.7115 |
| E71A, E71B, E71C - respiratory neoplasms | 4,202 | 1,840 | 6,042 | 2,854 | 1,467 | 4,321 | −32% | −20% | −28% | <0.0001 |
| G60A, G60B - digestive malignancy | 5,728 | 1,872 | 7,600 | 6,405 | 2,061 | 8,466 | 12% | 10% | 11% | <0.0001 |
| H61A, H61B - malignancy in the hepatobiliary system | 4,659 | 1,195 | 5,854 | 2,782 | 1,499 | 4,281 | −40% | 25% | −27% | <0.0001 |
| J06A, J07A - procedures of malignant breast | 2,505 | 914 | 3,418 | 2,358 | 822 | 3,180 | −6% | −10% | −7% | 0.0130 |
| J62A, J62B - malignant breast disorders | 735 | 296 | 1,031 | 707 | 196 | 903 | −4% | −34% | −12% | 0.0076 |
| L03A, L03B - kidney, urinary tract neoplasm procedures | 1,085 | 295 | 1,380 | 932 | 219 | 1,151 | −14% | −26% | −17% | <0.0001 |
| L62A, L62B - kidney, urinary tract neoplasm conditions | 457 | 383 | 841 | 410 | 291 | 701 | −10% | −24% | −17% | 0.0008 |
| M60A. M60B - malignancy male reproductive system | 452 | 433 | 884 | 361 | 326 | 687 | −20% | −25% | −22% | <0.0001 |
| N60A, N60B - malignancy female reproductive system | 1,511 | 540 | 2,051 | 817 | 447 | 1,264 | −46% | −17% | −38% | <0.0001 |
| R01 to R04 - neoplastic procedures, lymphoma, leukemia, and other hematol. | 1,530 | 594 | 2,124 | 1,277 | 487 | 1,764 | −17% | −18% | −17% | <0.0001 |
| R60 to R62 - neoplastic conditions, lymphoma, leukemia, and other hematol. | 7,672 | 2,229 | 9,901 | 6,475 | 2,277 | 8,752 | −16% | 2% | −12% | <0.0001 |
|
|
|
|
|
|
|
| – | – | – |
|
Source: CHIF and authors calculation.
Figure 4Incidence Rate Ratio Cancer and Neoplasm related DRGs during 2020 as compared to period 2017–2019.